Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Burosumab - Kyowa Hakko Kirin Pharma/Ultragenyx Pharmaceutical

Drug Profile

Burosumab - Kyowa Hakko Kirin Pharma/Ultragenyx Pharmaceutical

Alternative Names: Anti-FGF23 monoclonal antibody; Anti-fibroblast growth factor 23 monoclonal antibody; burosumab-twza; Crysvita; FGF23; KRN-23; UX 023

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko Kirin
  • Developer Kyowa Hakko Kirin; Kyowa Kirin; Ultragenyx Pharmaceutical
  • Class Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Fibroblast growth factor 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - X-linked dominant hypophosphataemic rickets; Osteomalacia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteomalacia; X-linked dominant hypophosphataemic rickets
  • Phase II Nevus

Most Recent Events

  • 01 Oct 2021 Biomarkers information updated
  • 07 Sep 2021 Registered for Osteomalacia (In adults) in Canada (SC)
  • 06 Aug 2021 Registered for X-linked dominant hypophosphataemic rickets in Singapore (SC) prior to August 2021 (Kyowa Hakko Kirin pipeline, August 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top